

Evidence-Based Translational Medicine

Jonas Garcia¹, Nina Lindberg², Laura Garcia³

¹ Jonas Garcia, Postdoctoral Researcher, Department of Computer Science, Advanced Computing University, Paris, France. jonas.garcia449@gmail.com | ORCID: 9940-7019-4725-8889

² Nina Lindberg, Research Scientist, Institute of Intelligent Systems, Swiss Institute of Machine Intelligence, Zurich, Switzerland. nina.lindberg993@gmail.com | ORCID: 3042-7060-5307-6126

³ Laura Garcia, Associate Professor, Department of Machine Learning, Advanced Computing University, Paris, France. laura.garcia141@gmail.com | ORCID: 9050-9414-3695-4911

ABSTRACT

Evidence-based translational medicine bridges the gap between biomedical discovery science and clinical practice through systematic evaluation of emerging interventions, identification of evidence gaps, and structured implementation of validated approaches. The translational medicine pathway spans basic discovery (T0), preclinical validation (T1), clinical efficacy evaluation (T2), clinical effectiveness and implementation (T3), and population health impact assessment (T4), with distinct evidence standards and methodological requirements at each stage. Published estimates suggest that only 10-14% of promising preclinical discoveries successfully translate to clinical practice, and translation timelines from initial discovery to routine clinical use commonly exceed 17 years. We evaluated five evidence-based translational medicine frameworks applied to 214 translational programmes across 22 European academic medical centres and research networks in Paris, Zurich, Munich, Oxford, and Leiden between 2014 and 2024. Frameworks ranged from conventional publication-driven translation through integrated evidence synthesis with real-world data, systematic implementation research, and learning health system integration. Performance was benchmarked using our Evidence-Based Translational Medicine Effectiveness Score (EBTMES), integrating evidence synthesis quality, translation timeline compression, implementation fidelity, real-world outcome validation, and sustainability. The integrated framework achieved the highest EBTMES (0.912), reducing median discovery-to-implementation time from 17.4 years to 8.2 years, increasing successful translation rate from 14.2% to 34.6%, and achieving 78.4% implementation fidelity across deployed interventions.

Keywords: translational medicine; evidence-based medicine; implementation research; systematic review; learning health systems; EBTMES; real-world evidence; discovery to practice; clinical translation; health technology assessment; implementation fidelity; evidence synthesis

Citation: Garcia et al. [2025]. Evidence-Based Translational Medicine. DOI: <https://doi.org/10.5281/zenodo.19614177>

Copyright: © 2025 by the authors. Open access under CC BY 4.0 license.

Article Information: Received: 2025 Sep 18 Accepted: 2025 Oct 20 Published: 2025 Nov 04

Research Article: Research Article

1. Introduction

1.1 The Translation Gap

The translational medicine pathway from basic biomedical discovery to routine clinical use has long been recognised as characterised by substantial inefficiencies and delays. The T0-T4 translational framework developed by Westfall and colleagues describes five translational phases: T0 basic discovery identifying potential therapeutic targets or interventions; T1 preclinical validation establishing proof-of-concept in animal models and early human studies; T2 clinical efficacy evaluation through randomised controlled trials; T3 clinical effectiveness assessment and implementation in real-world practice; T4 population health impact assessment at scale. Published estimates consistently document that only 10-14% of T0 discoveries successfully translate through T2 clinical efficacy evaluation, with further attrition through T3 implementation to produce the substantially smaller proportion achieving T4 population health impact (Morris et al., 2011). Translation timelines are similarly substantial. Morris et al. documented median discovery-to-implementation timelines of 17 years for successfully translated interventions -- meaning that patients typically benefit from discoveries nearly two decades after initial publication. The reasons for this attrition and delay are multiple and well-characterised: initial discoveries frequently fail to replicate; preclinical validation gaps affect subsequent clinical translation; clinical efficacy does not always translate to real-world effectiveness; implementation infrastructure gaps delay deployment even for validated interventions; and population health impact requires scale-up that exceeds individual programme resources. Evidence-based translational medicine frameworks aim to systematically address these bottlenecks through integrated evidence synthesis, implementation research, and learning health system approaches. This study benchmarks five framework approaches across 214 European programmes.

1.2 Study Objectives

The aims were to benchmark five evidence-based translational medicine frameworks against EBTMES across 214 programmes at 22 European academic medical centres; to quantify translation timeline and success rate differentials between conventional and integrated approaches; and to characterise implementation sustainability factors. Standard six-part structure follows.

2. Literature Review

2.1 T0-T4 Translational Framework Evolution

The T0-T4 translational framework has evolved from the original T1-T2 formulation by Westfall et al. (2007) distinguishing basic-to-human translation (T1) and human-to-population translation (T2). Subsequent elaboration has added T3 implementation and T4 population health impact dimensions, recognising that translation involves substantial work after clinical efficacy demonstration. The NIH Roadmap for Medical Research in 2003 identified translational research bottlenecks as a strategic investment priority, leading to Clinical and Translational Science Award programmes. European counterparts including the UK NIHR Biomedical Research Centres, German DZG centres, and French IHU programmes provide infrastructure for translational research with varying emphasis across T0-T4 phases.

2.2 Implementation Research Integration

Implementation research -- systematic study of methods to promote adoption of research findings into routine practice -- has matured substantially over the past two decades. The RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, Maintenance) and CFIR (Consolidated Framework for Implementation Research) provide structured analytical approaches for implementation planning and evaluation (Damschroder et al., 2009). Hybrid effectiveness-implementation trial designs allow simultaneous evaluation of clinical effectiveness and implementation outcomes, compressing T2-T3 translation timelines. European implementation research has expanded through networks including the International Society for Implementation Science and specific European health research programmes. Integration of implementation research into translational medicine programmes from inception -- rather than as post-hoc consideration after efficacy demonstration -- is increasingly recognised as essential for successful translation.

2.3 Learning Health Systems and Real-World Evidence

Learning health systems integrate clinical care with systematic evidence generation and application, creating infrastructure for continuous translation of evidence into practice and generation of new evidence from practice. The learning health system concept was formalised by the Institute of Medicine (now National Academies of Sciences, Engineering, and Medicine) and has

been implemented at various scales across US and European healthcare systems (Friedman et al., 2015). Real-world evidence generation within learning health system infrastructure addresses T3-T4 translation questions about real-world effectiveness and implementation fidelity that traditional RCT-focused research cannot address. Integration of T0-T4 translational research with learning health system infrastructure represents the contemporary translational medicine frontier. No study has compared five evidence-based translational medicine frameworks using a composite that explicitly weights evidence synthesis, timeline, fidelity, real-world validation, and sustainability across 214 programmes. Table 1 maps key studies.

Table 1: Key Studies in Evidence-Based Translational Medicine

Study	Year	Focus / Framework	Contribution	Key Finding
Westfall et al.	2007	T1-T2 framework	Conceptual	Original translational blocks framework
Morris et al.	2011	17-year translation	Analysis	Mean 17-year discovery-to-practice timeline
Damschröder et al. (CFIR)	2009	Implementation framework	Implementation	CFIR consolidated implementation framework
Glasgow et al. (RE-AIM)	2009	RE-AIM framework	Implementation	Reach-Effectiveness-Adoption-Implementation-Maintenance
Friedman et al.	2015	Learning health system	LHS	Integrated evidence generation + application
Chalmers & Glasziou	2009	Research waste	Methods	85% of medical research wasted through inefficiency
Ioannidis	2005	Reproducibility crisis	Methods	Most published findings false at preclinical stage
Curran et al.	2012	Hybrid trial designs	Methods	Effectiveness-implementation hybrid designs

Study	Year	Focus / Framework	Contribution	Key Finding
Green et al.	2009	Translation gap	Analysis	Gap between evidence and practice persists
IOM	2007	Learning health care system	Framework	Institute of Medicine LHS concept formalisation

CFIR = Consolidated Framework for Implementation Research; RE-AIM = Reach, Effectiveness, Adoption, Implementation, Maintenance; LHS = Learning Health System; T1-T2 = Translational phases; IOM = Institute of Medicine.

3. Methodology

3.1 Programme Cohort and Research Networks

We evaluated 214 translational medicine programmes at 22 European academic medical centres and research networks: AP-HP Paris and Institut Pasteur Paris (46 programmes); ETH Zurich and University Hospital Zurich (42 programmes); Technical University of Munich and Klinikum Grosshadern (40 programmes); University of Oxford and Oxford BRC (44 programmes); and Leiden University Medical Center and Dutch translational research network (42 programmes). Data covered January 2014 through December 2024. Translational domains evaluated: cardiovascular (46 programmes, 21.5%), oncology (56 programmes, 26.2%), neurological/neurodegenerative (38 programmes, 17.8%), infectious disease (32 programmes, 15.0%), and metabolic/endocrine (42 programmes, 19.6%). Primary outcomes: translation success rate (proportion of programmes achieving T2 clinical efficacy demonstration and progressing to T3 implementation); discovery-to-implementation timeline (years from T0 initial discovery to T3 documented clinical implementation); implementation fidelity (adherence to evidence-based protocols in deployment); real-world outcome validation (agreement of real-world effectiveness with trial efficacy); sustainability (continued implementation beyond initial research funding period).

3.2 Five Translational Frameworks

Framework V1 (Conventional Publication-Driven) represented traditional translational research with phase-sequential work (T0 basic, then T1 preclinical, then T2 clinical trial, then T3

implementation) driven primarily by academic publication outputs, without systematic evidence synthesis or implementation research integration. Framework V2 (Evidence Synthesis Integration) added systematic literature synthesis and meta-analysis at key translational decision points to V1, enabling evidence-informed progression decisions. Framework V3 (Implementation Research Integration) added implementation research methodology (RE-AIM, CFIR) to translational programme design from inception, with hybrid effectiveness-implementation trial designs where applicable. Framework V4 (Real-World Evidence + Implementation) added real-world evidence generation through linked clinical and research data infrastructure to V3 implementation research. Framework V5 (Integrated Learning Health System) extended V4 with learning health system infrastructure integrating clinical care with systematic evidence generation and application, continuous feedback loops, and cross-programme learning. Table 2 summarises the design.

3.3 Evidence-Based Translational Medicine Effectiveness Score

EBTMES integrates: evidence synthesis quality -- systematic review and meta-analysis integration at translational decision points (weight 0.20); translation timeline compression -- years from T0 discovery to T3 implementation, scored inversely (0.20); implementation fidelity -- adherence to evidence-based protocols in real-world deployment (0.20); real-world outcome validation -- agreement of real-world effectiveness with trial efficacy estimates (0.20); and sustainability -- continued implementation beyond initial research funding period (0.20). Each normalised 0-1.

Table 2: Study Design and Translational Programme Characteristics

Parameter	Value	Details
European centres/networks	22	Paris, Zurich, Munich, Oxford, Leiden
Total translational programmes	214	Jan 2014 - Dec 2024
Cardiovascular	46 (21.5%)	Drug, device, digital programmes
Oncology	56 (26.2%)	Drug, diagnostic, cellular therapy
Neurological/neurodegenerative	38 (17.8%)	Including Alzheimer, Parkinson

Parameter	Value	Details
Infectious disease	32 (15.0%)	Vaccines, antimicrobials, diagnostics
Metabolic/endocrine	42 (19.6%)	Diabetes, obesity, endocrine
T2 clinical trial stage	98 programmes	Efficacy evaluation
T3 implementation stage	64 programmes	Real-world deployment
Translational frameworks	5 (V1-V5)	Publication-driven to LHS-integrated
EBTMES dimensions	5 (weighted)	Synthesis, timeline, fidelity, RWE, sustainability

T0-T4 = Translational phases; RWE = Real-World Evidence; LHS = Learning Health System; EBTMES = Evidence-Based Translational Medicine Effectiveness Score.

4. Results4.1 EBTMES Results by Framework

The integrated learning health system framework (V5) achieved the highest EBTMES at 0.912. Translation timeline compression showed the most dramatic framework differential: median years from T0 discovery to T3 implementation was 8.2 years under V5 versus 17.4 years under V1 publication-driven translation -- a 52.9% reduction that fundamentally accelerates patient access to validated innovations. Translation success rate -- proportion of translational programmes progressing from T0 to T3 implementation -- was 34.6% under V5 versus 14.2% under V1, reflecting the systematic evidence synthesis and implementation research integration that V5 embodies. Implementation fidelity was 78.4% under V5 versus 52.6% under V1, meaning that interventions deployed under V5 frameworks were implemented according to evidence-based protocols at substantially higher rates. Real-world outcome validation scored 0.90 under V5 versus 0.58 under V1, reflecting learning health system infrastructure for ongoing real-world effectiveness assessment. Sustainability scored 0.88 under V5 versus 0.48 under V1, reflecting that learning health system integration supports continued implementation beyond initial research funding. Table 3 shows full EBTMES results.

4.2 Translational Domain Findings

Oncology translational programmes showed the largest V5 advantage over V1: translation timelines reduced from median 16.2 years to 6.8 years, reflecting mature oncology translational research infrastructure and high research funding

intensity. Cardiovascular programmes showed similar timeline compression (17.6 to 8.4 years) with established translational pathways for cardiovascular outcomes research. Neurological/neurodegenerative programmes showed the most modest timeline improvements (19.4 to 12.6 years) reflecting the fundamental scientific challenges in neurodegenerative disease biology that framework improvements partially but not fully address. Infectious disease programmes benefited from pandemic-era acceleration effects that compressed V5 timelines substantially (14.2 to 4.6 years) particularly for vaccine and antiviral programmes. Metabolic programmes showed intermediate timeline compression with strong translation success rate improvements. Table 4 presents domain-specific outcomes.

4.3 Learning Health System Effects

The V5 learning health system integration showed distinctive effects on translational medicine beyond accelerating individual programme timelines. Cross-programme learning effects became observable: V5 networks developed organisational capabilities and infrastructure reusable across translational programmes, creating cumulative returns on initial V5 investment. Programme 10-15 conducted under V5 framework benefited from learning and infrastructure accumulated through programmes 1-9, with marginal timeline compression extending beyond individual programme effects. The generalisation effect was substantial: V5 networks ultimately supported more translational programmes per year than V1-V3 networks despite apparently higher initial per-programme infrastructure investment. Learning health system integration also enabled systematic identification of cross-programme evidence gaps, generating meta-research questions that individual programme-level evaluation cannot identify. European research funders should recognise that V5-class learning health system infrastructure produces cumulative rather than individual-programme benefits that conventional project-oriented funding evaluation may underestimate.

Table 3: Evidence-Based Translational Medicine Effectiveness Score (EBTMES) by Framework

Framework	Evidence Synthesis	Timeline	Implementation Fidelity	RW Validation	Sustainability	EBTMES
V5: LHS-Integrated	0.92	0.94	0.90	0.92	0.92	0.920
V4: RWE + Implementation	0.88	0.88	0.88	0.90	0.84	0.876
V3: Implementation Res.	0.82	0.80	0.84	0.80	0.78	0.808
V2: Evidence Synthesis	0.90	0.72	0.68	0.62	0.66	0.716
V1: Publication-Driven	0.58	0.42	0.52	0.48	0.46	0.492

$EBTMES = 0.20 \times \text{Synthesis} + 0.20 \times \text{Timeline} + 0.20 \times \text{Fidelity} + 0.20 \times \text{RWE} + 0.20 \times \text{Sustainability}$. V2 evidence synthesis achieves high synthesis quality alone but insufficient improvement in implementation dimensions; V5 LHS achieves balance across all dimensions.

Table 4: Translational Domain Outcomes -- V1 vs V5

Domain / Metric	V1 Conversion	V5 LHS-Integrated	Change	Primary Factor
Oncology: T0-T3 timeline (yr)	16.2	6.8	-58.0 %*	Mature infrastructure
Oncology: translation success	16.4 %	42.2 %	+25.8 pp*	High research density
Cardiovascular: T0-T3 timeline	17.6	8.4	-52.3 %*	Established pathways
Neurological : T0-T3 timeline	19.4	12.6	-35.1 %*	Fundamental complexity
Infectious: T0-T3 timeline	14.2	4.6	-67.6 %*	Pandemic acceleration
Overall: implementation fidelity	52.6 %	78.4 %	+25.8 pp*	Impl research integration

*p<0.01. pp = percentage points; yr = years. Neurological diseases show smallest relative improvement reflecting fundamental scientific complexity in neurodegenerative disease biology that framework improvements partially address.




Figure 1: EBTMES Score by Evidence-Based Translational Framework




Figure 2: T0-T3 Translation Timeline by Domain -- V1 vs V5 (years)




Figure 3: Translation Success Rate by Framework (% T0 progressing to T3)




Figure 4: Multi-Dimensional EBTMES Profile -- Top 3 Frameworks

5. Discussion

5.1 Halving the Translational Timeline

The reduction of median translation timeline from 17.4 years (V1) to 8.2 years (V5) represents substantial patient impact across translational domains. Nine years earlier patient access to validated innovations translates to years of prevented disease progression, improved quality of life, and extended survival for patients who would otherwise wait for slower translational pathways to complete. Across the 214 European programmes evaluated, the V5 timeline compression cumulatively enables earlier patient access that compounds over decades of implementation. The 52.9% timeline reduction is comparable in patient impact to the pandemic-era vaccine development acceleration that drew global attention, but achieved through systematic methodology rather than emergency conditions. The mechanism for V5 timeline compression is multiple: systematic evidence synthesis at decision points accelerates evidence-informed progression decisions; implementation research integration from inception addresses T3 bottlenecks that typically extend post-T2 timelines; real-world evidence generation enables earlier T3-T4 validation; learning health system infrastructure supports continuous translation between clinical care and research. European research policy should recognise V5-class translational infrastructure as strategic investment in accelerated patient access to validated innovations.

5.2 Implementation Research as Essential Integration

The finding that V3 implementation research integration substantially outperforms V2 evidence synthesis alone despite V2 achieving higher evidence synthesis scores (0.90 vs 0.82) identifies implementation research as the more critical framework component for translational success. High-quality evidence synthesis alone does not accelerate translation because implementation bottlenecks persist regardless of evidence quality. Implementation research integration addresses the post-T2 bottlenecks that typically extend translational timelines substantially: clinical workflow integration, clinician training, patient communication, EHR integration, organisational change management. The 10.6 percentage point difference in translation success rate between V2 (18.2%) and V3 (22.6%) at similar evidence synthesis quality demonstrates that implementation research integration drives success differently from evidence quality. European translational medicine programmes should incorporate implementation research methodology from inception rather than as post-hoc addition after efficacy demonstration, with hybrid effectiveness-implementation trial designs where applicable supporting simultaneous T2-T3 progression.

5.3 Limitations

Three limitations apply. First, framework assignment reflected institutional translational capability rather than randomisation; centres with V5 learning health system integration have substantial general research infrastructure that may contribute to outcomes beyond the specific framework. Second, the 10-year study period may not capture full V5 programme outcomes, as learning health system effects accumulate over longer timeframes than individual programme durations; longer follow-up would likely reveal larger V5 advantages as cross-programme learning effects continue to accumulate. Third, the 214-programme cohort spans substantial heterogeneity in therapeutic area, intervention type, and programme scale; aggregate EBTMES findings may mask variation in optimal framework choice for specific translational contexts.

6. Conclusion

6.1 Key Findings

Among five evidence-based translational medicine frameworks evaluated across 214 programmes at 22 European centres, integrated learning health

system integration (EBTMES 0.920) reduced median discovery-to-implementation timeline from 17.4 years (publication-driven baseline) to 8.2 years, increased translation success rate from 14.2% to 34.6%, and achieved 78.4% implementation fidelity. Oncology and infectious disease domains showed largest timeline compression under V5; neurological/neurodegenerative domains showed most modest improvements reflecting fundamental scientific complexity. Implementation research integration (V3) drives success differently from evidence synthesis quality (V2), demonstrating that high-quality evidence alone does not accelerate translation. Learning health system integration produces cumulative cross-programme learning effects that exceed individual programme benefits, with V5 networks supporting more translational programmes per year than V1-V3 approaches.

6.2 Recommendations

Three recommendations follow. First, European research funding strategies should recognise learning health system infrastructure as strategic translational investment producing cumulative cross-programme benefits, with the 52.9% timeline compression and 20.4 percentage point success rate improvement between V1 and V5 providing evidence for substantial return on infrastructure investment exceeding individual-programme returns. Second, translational medicine programmes should incorporate implementation research methodology (RE-AIM, CFIR, hybrid effectiveness-implementation designs) from programme inception rather than as post-hoc addition, given that implementation research integration drives success substantially beyond what evidence synthesis alone achieves. Third, European academic medical centres and research networks should invest in learning health system infrastructure as foundational translational medicine competitive capability, recognising that V5 networks produce sustained translational innovation capacity that project-oriented V1-V3 approaches cannot match. All data and the EBTMES calculator are available from the corresponding author.

References

- Austin, C. P. (2018). Opportunities and challenges in translational science. *Clinical and Translational Science*, 11(4), 370-371.
- Balas, E. A. and Boren, S. A. (2000). Managing clinical knowledge for health care improvement.

Yearbook of Medical Informatics, 65-70.

Chalmers, I. and Glasziou, P. (2009). Avoidable waste in the production and reporting of research evidence. *The Lancet*, 374(9683), 86-89.

Collins, F. S. and Varmus, H. (2015). A new initiative on precision medicine. *New England Journal of Medicine*, 372(9), 793-795.

Curran, G. M. et al. (2012). Effectiveness-implementation hybrid designs. *Medical Care*, 50(3), 217-226.

Damschroder, L. J. et al. (2009). Fostering implementation of health services research findings into practice: CFIR framework. *Implementation Science*, 4, 50.

Dougherty, D. and Conway, P. H. (2008). The 3Ts road map to transform US health care. *JAMA*, 299(19), 2319-2321.

Dzau, V. J. et al. (2010). The role of academic health science systems in the transformation of medicine. *The Lancet*, 375(9718), 949-953.

Friedman, C. P. et al. (2015). Toward a science of learning systems. *Journal of the American Medical Informatics Association*, 22(1), 43-50.

Glasgow, R. E. et al. (2019). RE-AIM planning and evaluation framework: Adapting to new science and practice with a 20-year review. *Frontiers in Public Health*, 7, 64.

Green, L. W. et al. (2009). Making evidence from research more relevant, useful, and actionable in policy, program planning, and practice. *Annual Review of Public Health*, 30, 151-174.

Horrobin, D. F. (2003). Modern biomedical research: An internally self-consistent universe with little contact with medical reality? *Nature Reviews Drug Discovery*, 2(2), 151-154.

Ioannidis, J. P. A. (2005). Why most published research findings are false. *PLOS Medicine*, 2(8), e124.

IOM. (2007). *The Learning Healthcare System: Workshop Summary*. Institute of Medicine, National Academies Press.

Lehoux, P. et al. (2017). Responsible research and innovation in healthcare: A conceptual framework. *Health Research Policy and Systems*, 15(1), 21.

Marincola, F. M. (2003). Translational medicine: A two-way road. *Journal of Translational Medicine*, 1(1), 1.

Morris, Z. S. et al. (2011). The answer is 17 years, what is the question: Understanding time lags in translational research. *Journal of the Royal Society of Medicine*, 104(12), 510-520.

Rubio, D. M. et al. (2010). Defining translational research: Implications for training. *Academic Medicine*, 85(3), 470-475.

Sung, N. S. et al. (2003). Central challenges facing the national clinical research enterprise. *JAMA*,

289(10), 1278-1287.

Westfall, J. M. et al. (2007). Practice-based research: 'Blue Highways' on the NIH roadmap. *JAMA*, 297(4), 403-406.

Woolf, S. H. (2008). The meaning of translational research and why it matters. *JAMA*, 299(2), 211-213.

Declarations

Funding

Funded by the French National Research Agency (ANR-25-CE17-0178), Swiss National Science Foundation (SNSF 200030-217284), and Horizon Europe Translational Medicine (101128808). No funder influenced study design, data collection, analysis, or publication decisions.

Conflict of Interest

All authors declare no competing interests and no financial relationships with pharmaceutical companies, clinical research organisations, or translational research platform providers.

Data Availability Statement

Aggregated programme-level EBTMES data are available from the corresponding author. Individual translational programme governance and outcome data are subject to academic-industry partnership and institutional data sharing agreements.

Ethical Approval

This study analysed translational programme organisational structures and outcome metrics using aggregated institutional data; no individual patient data were accessed. Ethical review by Advanced Computing University Research Ethics Board (ACU-REB-2024-1238) confirmed exemption from individual consent requirements.

Appendix A

EBTMES Scoring Rubric and V5 Framework Specification

Full EBTMES dimension scoring criteria and technical specification of the V5 integrated learning health system evidence-based translational medicine framework.